{"entities":{"Q6690225":{"pageid":14409206,"ns":120,"title":"Item:Q6690225","lastrevid":54735554,"modified":"2026-01-29T20:21:38Z","type":"item","id":"Q6690225","labels":{"en":{"language":"en","value":"Data from: Ten-year survival trends of neovascular age-related macular degeneration at first presentation"}},"descriptions":{"en":{"language":"en","value":"Dataset published at Zenodo repository."}},"aliases":{},"claims":{"P31":[{"mainsnak":{"snaktype":"value","property":"P31","hash":"dae155fd0809a7906855cd4fa50dd7d71bed552b","datavalue":{"value":{"entity-type":"item","numeric-id":56885,"id":"Q56885"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$0D3D31A6-B6FB-44A8-B4EC-6831E7FCF315","rank":"normal"}],"P1459":[{"mainsnak":{"snaktype":"value","property":"P1459","hash":"08a3250b23724207f6b91fb861369eb09387cf21","datavalue":{"value":"Background: To describe 10-year trends in visual outcomes, anatomical outcomes, and treatment burden of patients receiving anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD).  Methods: Retrospective cohort study of treatment-na\u00efve, first-affected eyes with nAMD started on ranibizumab before January 1, 2009. The primary outcome was time to best-corrected visual acuity (BCVA) falling \u2264 35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters after initiating anti-VEGF therapy. Secondary outcomes included time to BCVA reaching \u2265 70 letters; proportion of eyes with BCVA \u2265 70 and \u2264 35 letters at 10 years; mean trend of BCVA and central retinal thickness (CRT) over 10 years; and mean number of injections.  Results: For our cohort of 103 patients, Kaplan-Meier analyses demonstrated median time to BCVA reaching \u226435 and \u226570 letters were 37.8 (95% CI 22.2-65.1) and 8.3 (95% CI 4.8-20.9) months after commencing anti-VEGF therapy, respectively. At the final follow-up, BCVA was \u226435 letters and \u226570 letters in 41.1% and 21%, respectively, in first-affected eyes, whilst this was the case for 5.4% and 48.2%, respectively, in a patient's better-seeing eye. Mean injection number was 37.0 \u00b1 24.2 per eye and 53.6 \u00b1 30.1 at patient-level (63.1% of patients required injections in both eyes).\u00a0  Conclusions: The chronicity of nAMD disease and its management highlights the importance of long-term visual prognosis. Our analyses suggest that one in five patients will retain good vision (BCVA \u226570 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet one in two patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment of nAMD is associated with better visual outcomes.","type":"string"},"datatype":"string"},"type":"statement","id":"Q6690225$F777F0BB-31D1-4B1B-AE8D-5AB8C189B986","rank":"normal"}],"P28":[{"mainsnak":{"snaktype":"value","property":"P28","hash":"306d463deb5766e771e19d6cb06ee40cfd980ebb","datavalue":{"value":{"time":"+2020-09-25T00:00:00Z","timezone":0,"before":0,"after":0,"precision":11,"calendarmodel":"http://www.wikidata.org/entity/Q1985727"},"type":"time"},"datatype":"time"},"type":"statement","id":"Q6690225$443B8131-B19A-48D8-8D25-A47A9D054FEC","rank":"normal"}],"P16":[{"mainsnak":{"snaktype":"value","property":"P16","hash":"35d759f9befaf993b06f2c4abb88f305e2bee712","datavalue":{"value":{"entity-type":"item","numeric-id":132280,"id":"Q132280"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$73146B8E-ED95-4214-926B-8F0A4D0AABDD","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"cf65fc23ce36e62d3932ffbd47d4655fe91a630b","datavalue":{"value":{"entity-type":"item","numeric-id":6690213,"id":"Q6690213"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$3ADCF722-B7C5-479B-BFC8-7D561E31E667","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"e34dca85d41d045da6059cc04dffe8f8113650c9","datavalue":{"value":{"entity-type":"item","numeric-id":6690214,"id":"Q6690214"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$50874655-CD8D-40FF-97B6-0A3BFFDEF995","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"f87972888a48c6ef2c1fda74660d8eb78e346db9","datavalue":{"value":{"entity-type":"item","numeric-id":6690215,"id":"Q6690215"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$AF72DCEA-1CA0-41BF-BE1F-9016AC9BF3A7","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"d53339ca609dcd17353b7bbccb4f4abb1867ae51","datavalue":{"value":{"entity-type":"item","numeric-id":6690216,"id":"Q6690216"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$3221716D-BCF9-4108-A2A0-95A46F8069ED","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"b6fd9575afecbbe434c6ab17c44a7b4bde29fac4","datavalue":{"value":{"entity-type":"item","numeric-id":6690217,"id":"Q6690217"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$A970681E-0865-4C6E-8443-BB785875A938","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"c94828b80c4bbfb47a7e03da7ea76afafe97a617","datavalue":{"value":{"entity-type":"item","numeric-id":6690218,"id":"Q6690218"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$A7B32E3B-8CD6-455F-8243-39086D2EBCAF","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"e35b4e25d4bb71520814f2a4739f29cbd5cb65bb","datavalue":{"value":{"entity-type":"item","numeric-id":6690219,"id":"Q6690219"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$9753E310-0CDD-403F-9D28-68DB8D749BF3","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"31fa52ca6ff1473756fe1704d8bbb46434cdab4f","datavalue":{"value":{"entity-type":"item","numeric-id":6690220,"id":"Q6690220"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$8CDFC2EE-2370-4C35-B2E0-613348F38AAA","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"b04fdb9683401fe5b3a5728550e14fcb3c4aeee4","datavalue":{"value":{"entity-type":"item","numeric-id":6690221,"id":"Q6690221"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$EA015367-BB83-4B1A-8FB9-23DD88C47EE9","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"be63e097b3a525a64a1db443ff07ed0cfd34923a","datavalue":{"value":{"entity-type":"item","numeric-id":6690222,"id":"Q6690222"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$AF982E62-1D95-483F-BA7A-74DD48A85368","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"c2021d694b47ab69ad391308b379983c689a079d","datavalue":{"value":{"entity-type":"item","numeric-id":6690223,"id":"Q6690223"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$B0C0F8F6-16D9-42D4-8746-81ED553F0BCF","rank":"normal"},{"mainsnak":{"snaktype":"value","property":"P16","hash":"dd5f5ac2a91c004a978292e68a7619cf5707b32a","datavalue":{"value":{"entity-type":"item","numeric-id":6690224,"id":"Q6690224"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$9DFADD6B-0495-4FF9-856D-24D20390B84B","rank":"normal"}],"P227":[{"mainsnak":{"snaktype":"value","property":"P227","hash":"2514bd678a086353303af1c01226654c6f23068e","datavalue":{"value":"4086324","type":"string"},"datatype":"external-id"},"type":"statement","id":"Q6690225$78806A5E-615C-4F1B-9C28-79159A87487B","rank":"normal"}],"P27":[{"mainsnak":{"snaktype":"value","property":"P27","hash":"aae1ef4e5730e77e06f755d9f28373fa956fd124","datavalue":{"value":"10.5281/zenodo.4086324","type":"string"},"datatype":"external-id"},"type":"statement","id":"Q6690225$BB144FCA-FE05-4F6E-B8BB-0E2DA897319C","rank":"normal"}],"P1460":[{"mainsnak":{"snaktype":"value","property":"P1460","hash":"d1e8073b72a070520efd3d14d4b3d2d3d03859e2","datavalue":{"value":{"entity-type":"item","numeric-id":5984635,"id":"Q5984635"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q6690225$F03BD6AE-DDE1-438F-BAC1-3A9EAEE35E5F","rank":"normal"}]},"sitelinks":{"mardi":{"site":"mardi","title":"Data from: Ten-year survival trends of neovascular age-related macular degeneration at first presentation","badges":[],"url":"https://portal.mardi4nfdi.de/wiki/Data_from:_Ten-year_survival_trends_of_neovascular_age-related_macular_degeneration_at_first_presentation"}}}}}